These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Feb. 26 through March 4, 2026. Source: VerityData

Activist Filings

UniFirst $(UNF)$ River Road Asset Management lowered its stake in the workplace-clothing provider to 733,118 shares. River Road did so through the sale of 134,347 UniFirst shares from Dec. 29, 2025, through Feb. 25, 2026, at per share prices ranging from $194.73 to $241.51, after buying 9,964 shares from Dec. 29 through Jan. 16 at $193.47 to $210.45. In a Nov. 24 open shareholder letter, River Road criticized UniFirst's board for refusing to engage with Cintas on its acquisition proposal for $275 per share, which it called a breach of fiduciary duty. River Road also urged the board to explore strategic alternatives, including a sale, and said that it intended to vote for Engine Capital's nominees at the Dec. 15, 2025, annual meeting.

Following the latest sales, River Road continues to own 5% of UniFirst's outstanding stock. Shares of UniFirst have gained roughly 19.5% in value since the beginning of this year.

Increases in Holdings

Elastic(ESTC) Pictet Asset Management raised its stake in the data software company to 6,412,736 shares. Pictet Asset Management did so through the purchase of 1,889,348 Elastic shares from Jan. 5 through Feb. 27 at per share prices ranging from $52.01 to $75.61, and slightly offset those purchases through the sale of 15,870 shares from Dec. 31 through Feb. 25 at $53.34 to $76.69.

Following the latest purchases, Pictet Asset Management owns a 6.2% stake in Elastic's outstanding stock. Shares of Elastic have lost approximately 28.5% of their value since the beginning of this year.

Zura Bio(ZURA) AI Biotechnology raised its stake in the clinical-stage immunology company to 19,699,071 shares. AI Biotechnology did so through the purchase of 2,000,000 Zura shares on Feb. 26 at an average price of $6.25 per share pursuant to a registered public offering.

Following the purchase, AI Biotechnology owns an 18.2% stake in Zura Bio's outstanding stock. Shares of Zura Bio have gained roughly 26.0% in value since the beginning of this year.

Decreases in Holdings

Five9$(FIVN)$ Pictet Asset Management reduced its stake in the contact center software provider to 2,872,185 shares. Pictet Asset Management did so through the sale of 3,135,658 Five9 shares from Feb. 13 through Feb. 26 at per share prices ranging from $16.65 to $19.71, and slightly offset those sales through the purchase of 2,659 shares on Jan. 6 at $19.74 per share.

Following the latest sales, Pictet Asset Management continues to own a 3.8% stake in Five9's outstanding stock, placing Pictet Asset Management below the 5% threshold that would require it to report further sales. Shares of Five9 have lost roughly 4.9% of their value since the beginning of this year.

Email: editors@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

March 06, 2026 20:41 ET (01:41 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.